Skip to main content Skip to footer

Apixaban level

Test Alias / Common Abbreviations

DOAC; Anticoagulant;

 

Department


Haematology


Test Purpose  


To determine apixaban levels.

Apixaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa. Once bound to apixaban, factor Xa can no longer contribute to the coagulation process, thereby inducing an anticoagulant effect. Licensed indications for apixaban include the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, and the treatment/prevention of pulmonary embolism/deep vein thrombosis.

Monitoring of apixaban is NOT routinely required. 

A normal PT/APTT does NOT exclude clinically significant anticoagulant effect in patients receiving DOAC.

The Apixaban Level  may be helpful to monitor anticoagulation levels in certain cohorts of patients: 
•    Trough levels are helpful to identify dose accumulation e.g. in liver and renal impairment.
•    Peak levels are helpful to confirm adequate dosing e.g. IBD, post bowel surgery. 
•    Random testing may be helpful in emergency situations e.g. prior to urgent surgery or following major bleeding.


Important Requesting Instructions


Requests must be approved by Clinical Haematology.


Urgent requests must be discussed with the laboratory.

Sample Collection Instructions


Venous whole blood is preferred. For other sample types please discuss with the laboratory.
Timing of sample: 


•    Trough levels - 12 hours post dose
•    Peak levels - 3 hours post dose

Sample Transport & Stability Information


Packaging must be compliant with Dangerous Good Safety Advisor (DGSA)   requirements click here for more information.


Samples should be delivered to the laboratory within 2 hours of venepuncture.

 

Sample Type, Container & Volume

2 X Citrate (Blue)

A close-up of a vial

AI-generated content may be incorrect.

 

Must be filled to minimum fill line.

 

Turnaround Time

Urgent – 4 hours (Mon-Fri, 09:00 – 17:00)

Routine – 1 week

 

Interpretation is dependent on clinical situation, apixaban dose and timing of the test.

Apixaban levels <50 ng/ml = likely NO clinically significant anticoagulant effect.

Results must be discussed with Clinical Haematology, click here for contact details.

Interpretation of apixaban levels is challenging for many reasons; including limited established therapeutic ranges and lack of high-quality evidence on how test results should guide individual patient care. 

Indication

Dose apixaban

Peak (ng/ml)

(5th – 95th percentile)

Trough (ng/ml)

(5th – 95th percentile)

AF

5mg BD

171 (91-321)

103 (41-230)

2.5mg BD

123 (69-221)

 

Treatment PE/DVT

5mg BD

132 (59-302)

63 (22-177)

2.5mg BD

67 (30-153)

 

Expected plasma concentrations for apixaban according to clinical indication, dose and timing (2025 Mithoowani, 2024 Baker/British Society Haematology)

Results from urgent requests will be phoned to the requesting source.

Results may be affected by haemolysis, lipaemia and icterus.

Heparin contamination, including from heparinised lines, may cause spurious results.

This assay is not specific for apixaban.  Other factor Xa inhibitors, including low molecular weight heparin (LMWH), will cause interference.

The limit of detection is stated to be 6ng/ml.

The linear range is 15-1000ng/ml.

Requests indicating dual anticoagulation will be rejected.

Please note this assay is not currently UKAS accredited, pending assessment.

Updated On: 29.04.2025